| Scrip Code | 523642 |
|---|---|
| NSE Symbol | PIIND |
| MSEI Symbol | NOTLISTED |
| ISIN | INE603J01030 |
| Name of company | PI INDUSTRIES LIMITED |
| Type of company | Main Board |
| Class of security | Equity |
| Date of start of financial year | 01-04-2025 |
| Date of end of financial year | 31-03-2026 |
| Date of board meeting when results were approved | 19-05-2026 |
| Date on which prior intimation of the meeting for considering financial results was informed to the exchange | 11-05-2026 |
| Description of presentation currency | INR |
| Level of rounding used in financial results | Lakhs |
| Reporting Type | Quarterly |
| Reporting Quarter | Fourth quarter |
| Nature of report standalone or consolidated | Consolidated |
| Whether results are audited or unaudited for the quarter ended | Audited |
| Whether results are audited or unaudited for the Year to date for current period ended/year ended | Audited |
| Segment Reporting | Multi segment |
| Description of single segment | |
| Start date and time of board meeting | 19-05-2026 14:00:00 |
| End date and time of board meeting | 19-05-2026 20:10:00 |
| Whether cash flow statement is applicable on company | Yes |
| Type of cash flow statement | Cash Flow Indirect |
| Declaration of unmodified opinion or statement on impact of audit qualification | Declaration of unmodified opinion |
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-01-2026 | 01-04-2025 |
| B | Date of end of reporting period | 31-03-2026 | 31-03-2026 |
| C | Whether results are audited or unaudited | Audited | Audited |
| D | Nature of report standalone or consolidated | Consolidated | Consolidated |
| 1 | Income | ||
| Revenue from operations | 1,56,520.00 | 6,71,370.00 | |
| Other income | 7,560.00 | 31,070.00 | |
| Total income | 1,64,080.00 | 7,02,440.00 | |
| 2 | Expenses | ||
| (a) | Cost of materials consumed | 66,900.00 | 2,99,000.00 |
| (b) | Purchases of stock-in-trade | 1,610.00 | 16,800.00 |
| (c) | Changes in inventories of finished goods, work-in-progress and stock-in-trade | (2,520.00) | (32,470.00) |
| (d) | Employee benefit expense | 22,680.00 | 90,770.00 |
| (e) | Finance costs | 370.00 | 1,640.00 |
| (f) | Depreciation, depletion and amortisation expense | 10,670.00 | 40,660.00 |
| (f) | Other Expenses | ||
| 1 | Net Impairment losses on financial assets | 830.00 | 3,260.00 |
| 2 | Power, Fuel & Water | 6,600.00 | 27,360.00 |
| 3 | Environment & Pollution Control Expenses | 2,630.00 | 11,730.00 |
| 4 | Freight & Cartage | 1,340.00 | 4,400.00 |
| 5 | Advertisement & Sales Promotion | 2,910.00 | 9,880.00 |
| 6 | Travelling and Conveyance | 3,550.00 | 11,310.00 |
| 7 | Legal & professional fees | 3,140.00 | 10,960.00 |
| 8 | Repairs & Maintenance | 3,630.00 | 14,090.00 |
| 9 | Laboratory & Testing Charges | 1,770.00 | 5,370.00 |
| 10 | Other expenses | 7,760.00 | 28,950.00 |
| Total other expenses | 34,160.00 | 1,27,310.00 | |
| Total expenses | 1,33,870.00 | 5,43,710.00 | |
| 3 | Total profit before exceptional items and tax | 30,210.00 | 1,58,730.00 |
| 4 | Exceptional items | (200.00) | 10,310.00 |
| 5 | Total profit before tax | 30,010.00 | 1,69,040.00 |
| 6 | Tax expense | ||
| 7 | Current tax | 6,470.00 | 33,520.00 |
| 8 | Deferred tax | 3,560.00 | 4,010.00 |
| 9 | Total tax expenses | 10,030.00 | 37,530.00 |
| 10 | Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement | 0.00 | 0.00 |
| 11 | Net Profit Loss for the period from continuing operations | 19,980.00 | 1,31,510.00 |
| 12 | Profit (loss) from discontinued operations before tax | 0.00 | 0.00 |
| 13 | Tax expense of discontinued operations | 0.00 | 0.00 |
| 14 | Net profit (loss) from discontinued operation after tax | 0.00 | 0.00 |
| 15 | Share of profit (loss) of associates and joint ventures accounted for using equity method | 40.00 | 570.00 |
| 16 | Total profit (loss) for period | 20,020.00 | 1,32,080.00 |
| 17 | Other comprehensive income net of taxes | (4,060.00) | (2,040.00) |
| 18 | Total Comprehensive Income for the period | 15,960.00 | 1,30,040.00 |
| 19 | Total profit or loss, attributable to | ||
| Profit or loss, attributable to owners of parent | 15,960.00 | 1,30,040.00 | |
| Total profit or loss, attributable to non-controlling interests | 0.00 | 0.00 | |
| 20 | Total Comprehensive income for the period attributable to | ||
| Comprehensive income for the period attributable to owners of parent | |||
| Total comprehensive income for the period attributable to owners of parent non-controlling interests | |||
| 21 | Details of equity share capital | ||
| Paid-up equity share capital | 1,520.00 | 1,520.00 | |
| Face value of equity share capital | 1 | 1 | |
| 27 | Details of debt securities | ||
| 22 | Reserves excluding revaluation reserve | 11,21,530.00 | |
| 23 | Earnings per share | ||
| i | Earnings per equity share for continuing operations | ||
| Basic earnings (loss) per share from continuing operations | 13.2 | 87.06 | |
| Diluted earnings (loss) per share from continuing operations | 13.2 | 87.06 | |
| ii | Earnings per equity share for discontinued operations | ||
| Basic earnings (loss) per share from discontinued operations | 0 | 0 | |
| Diluted earnings (loss) per share from discontinued operations | 0 | 0 | |
| ii | Earnings per equity share | ||
| Basic earnings (loss) per share from continuing and discontinued operations | 13.2 | 87.06 | |
| Diluted earnings (loss) per share from continuing and discontinued operations | 13.2 | 87.06 | |
| 24 | Debt equity ratio | ||
| 25 | Debt service coverage ratio | ||
| 26 | Interest service coverage ratio | ||
| 27 | Disclosure of notes on financial results | Textual Information(1) | |
| Textual Information(1) | 1. The above Consolidated financial results were reviewed and recommended by the Audit Committee of the Company and approved by the Board of Directors at their meeting held on May 19, 2026. 2. The Consolidated financial results for all the periods presented have been prepared in accordance with the recognition and measurement principles of Ind AS notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended from time to time. 3. The Consolidated financial results include the results of the following entities namely, Parent Company - PI Industries Limited; Subsidiaries (including step down subsidiaries): (a) PI Health Sciences Limited (b) PI Health Sciences USA, LLC (c) PI Health Sciences Netherlands BV (d) Archimica S.p.A Italy (e) PI AgSciences Limited (Formerly known as Plant Health Care limited) (f) PI AgSciences, Inc. (Formerly known as Plant Health Care, Inc, Nevada) (g) Plant Health Care de Mexico S. de R.L. de C.V. (h) PI AgSciences (UK) Limited (Formerly known as Plant Health Care (UK) Limited) (i) PI AgSciences Spain, S.A (Formerly known as Plant Health Care España) (j) PI AgSciences Brasil Ltda (Formerly know as Plant Health Care Insumos Agricolas LTDA) (k) Jivagro Limited (l) PI Life Science Research Limited (m) PI Flowtech B.V. (n) PI Industries Management Consultancies LLC Dubai (o) PI Innoventures Limited (Formerly known as PILL Finance and Investments Limited) (p) PI Japan Co. Limited (q) PI Bioferma Private Limited (r) PI Fermachem Private Limited ;Controlled trust - PII ESOP Trust; Joint Venture - PI Kumiai Private Limited ; Associate - Solinnos Agro Sciences Private Limited. 4. The figures for the March quarter are the balancing figures between audited figures in respect of full financial year and the published unaudited year to date figures up to the third quarter of respective financial year. 5. The Company raised Rs 20,000 Mn during the quarter ended September 30, 2020 through Qualified Institutional Placement (QIP) of equity shares. Out of the funds received of Rs 19,750 Mn (net of expense of Rs 250 Mn), the Company invested Rs 18,419 Mn in its subsidiaries and Rs 1,331 Mn towards capital expenditure, thereby the entire QIP funds have been utilized during the year. 6. a) In April 2023, PI Health Sciences Limited (PIHS), a wholly owned subsidiary of the Company acquired 100% equity of Solis Pharmachem Private Limited and Therachem Research Medilab (India) Private Limited and specific assets of Therachem Research Medilab LLC, USA. The purchase consideration for the above included contingent consideration to be paid over a period of 6 years subject to achievement of specified business performance and to support for business development activities. Considering the performance of the acquired business since the acquisition, and the successful establishment of an experienced in-house global business development team, no longer requiring external business development support, the Company has renegotiated a mutually beneficial one-time settlement payment with erstwhile owners. This settlement has resulted in a write-back of the contingent consideration of Rs 1,260 million, which has been presented under Exceptional Item during the quarter ended December 31, 2025. b) Pursuant to the notification issued by the Ministry of Labour and Employment, multiple existing labour legislations have been consolidated into a unified framework comprising four Labour Codes, collectively referred to as the New Labour Codes which became effective from November 21, 2025. The Group has reassessed its employee benefit obligations in accordance with the revised definition of Wages. Considering that this impact is driven by a regulatory change and is non-recurring in nature, accordingly, an incremental liability of Rs 209 Mn has been recognised as an Exceptional Item during the quarter ended December 31, 2025 and Rs 20 Mn during the quarter ended March 31, 2026. The Ministry is in the process of notifying related rules to the New Labour Codes and impact of those will be evaluated and accounted for in the period in which they are notified. 7. Segment information as per Ind AS 108 Operating Segments is as per Annexure I. 8. The Board of Directors at their meeting held on May 19, 2026 have recommended final dividend of Rs 10 per equity share, subject to the approval of the shareholders in the ensuring Annual General Meeting. With this, total dividend for the year (including interim dividend of Rs 5 per equity share paid during the year) is Rs 15 per share. |
|---|
| Debt equity ratio | |
|---|---|
| Debt service coverage ratio | |
| Interest service coverage ratio |
| Particulars | Year ended (dd-mm-yyyy) | ||
|---|---|---|---|
| Date of start of reporting period | 01-04-2025 | ||
| Date of end of reporting period | 31-03-2026 | ||
| Whether results are audited or unaudited | Audited | ||
| Nature of report standalone or consolidated | Consolidated | ||
| Assets | |||
| 1 | Non-current assets | ||
| Property, plant and equipment | 3,67,830.00 | ||
| Capital work-in-progress | 75,500.00 | ||
| Investment property | |||
| Goodwill | 60,280.00 | ||
| Other intangible assets | 33,860.00 | ||
| Intangible assets under development | 27,490.00 | ||
| Biological assets other than bearer plants | |||
| Investments accounted for using equity method | 3,150.00 | ||
| Non-current financial assets | |||
| Non-current investments | 170.00 | ||
| Trade receivables, non-current | |||
| Loans, non-current | 0.00 | ||
| Other non-current financial assets | |||
| 1 | Other non-current financial assets | 17,140.00 | |
| Total of other non-current financial assets | 17,140.00 | ||
| Total non-current financial assets | 17,310.00 | ||
| Deferred tax assets (net) | 5,520.00 | ||
| Other non-current assets | |||
| 1 | Current Tax assets | 1,190.00 | |
| 2 | Other non-current assets | 2,770.00 | |
| Total of other non-current assets | 3,960.00 | ||
| Total non-current assets | 5,94,900.00 | ||
| 2 | Current assets | ||
| Inventories | 1,21,670.00 | ||
| Current financial asset | |||
| Current investments | 1,32,710.00 | ||
| Trade receivables, current | 2,31,990.00 | ||
| Cash and cash equivalents | 28,330.00 | ||
| Bank balance other than cash and cash equivalents | 1,89,900.00 | ||
| Loans, current | 120.00 | ||
| Other current financial assets | |||
| Total of other current financial assets | 3,240.00 | ||
| Total current financial assets | 5,86,290.00 | ||
| Current tax assets (net) | |||
| Other current assets | |||
| 1 | Other current assets | 41,510.00 | |
| Total of other current assets | 41,510.00 | ||
| Total current assets | 7,49,470.00 | ||
| 3 | Non-current assets classified as held for sale | ||
| 4 | Regulatory deferral account debit balances and related deferred tax Assets | ||
| Total assets | 13,44,370.00 | ||
| Equity and liabilities | |||
| 1 | Equity | ||
| Equity attributable to owners of parent | |||
| Equity share capital | 1,520.00 | ||
| Other equity | 11,21,530.00 | ||
| Total equity attributable to owners of parent | 11,23,050.00 | ||
| Non controlling interest | |||
| Total equity | 11,23,050.00 | ||
| 2 | Liabilities | ||
| Non-current liabilities | |||
| Non-current financial liabilities | |||
| Borrowings, non-current | 14,900.00 | ||
| Trade payables, non-current | |||
| (A) Total outstanding dues of micro enterprises and small enterprises | |||
| (B) Total outstanding dues of creditors other than micro enterprises and small enterprises | |||
| Total Trade payable | |||
| Other non-current financial liabilities | |||
| 1 | Lease Liabilities | 7,220.00 | |
| 2 | Other non-current financial liabilities | 14,370.00 | |
| Total of other non-current financial liabilities | 21,590.00 | ||
| Total non-current financial liabilities | 36,490.00 | ||
| Provisions, non-current | 3,320.00 | ||
| Deferred tax liabilities (net) | 3,840.00 | ||
| Deferred government grants, Non-current | |||
| Other non-current liabilities | |||
| Total of other non-current liabilities | |||
| Total non-current liabilities | 43,650.00 | ||
| Current liabilities | |||
| Current financial liabilities | |||
| Borrowings, current | 8,930.00 | ||
| Trade payables, current | |||
| (A) Total outstanding dues of micro enterprises and small enterprises | 7,250.00 | ||
| (B) Total outstanding dues of creditors other than micro enterprises and small enterprises | 90,130.00 | ||
| Total Trade payable | 97,380.00 | ||
| Other current financial liabilities | |||
| 1 | Lease Liabilities | 3,180.00 | |
| 2 | Other current financial liabilities | 53,880.00 | |
| Total of other current financial liabilities | 57,060.00 | ||
| Total current financial liabilities | 1,63,370.00 | ||
| Other current liabilities | 9,820.00 | ||
| 1 | Other current liabilities | 9,820.00 | |
| Total of other current liabilities | 9,820.00 | ||
| Provisions, current | 3,970.00 | ||
| Current tax liabilities (Net) | 510.00 | ||
| Deferred government grants, Current | |||
| Total current liabilities | 1,77,670.00 | ||
| 3 | Liabilities directly associated with assets in disposal group classified as held for sale | ||
| 4 | Regulatory deferral account credit balances and related deferred tax liability | ||
| Total liabilities | 2,21,320.00 | ||
| Total equity and liabilites | 13,44,370.00 | ||
| Disclosure of notes on assets and liabilities | Textual Information(1) | ||
| Textual Information(1) | 1. The above Consolidated financial results were reviewed and recommended by the Audit Committee of the Company and approved by the Board of Directors at their meeting held on May 19, 2026. 2. The Consolidated financial results for all the periods presented have been prepared in accordance with the recognition and measurement principles of Ind AS notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended from time to time. 3. The Consolidated financial results include the results of the following entities namely, Parent Company - PI Industries Limited; Subsidiaries (including step down subsidiaries): (a) PI Health Sciences Limited (b) PI Health Sciences USA, LLC (c) PI Health Sciences Netherlands BV (d) Archimica S.p.A Italy (e) PI AgSciences Limited (Formerly known as Plant Health Care limited) (f) PI AgSciences, Inc. (Formerly known as Plant Health Care, Inc, Nevada) (g) Plant Health Care de Mexico S. de R.L. de C.V. (h) PI AgSciences (UK) Limited (Formerly known as Plant Health Care (UK) Limited) (i) PI AgSciences Spain, S.A (Formerly known as Plant Health Care España) (j) PI AgSciences Brasil Ltda (Formerly know as Plant Health Care Insumos Agricolas LTDA) (k) Jivagro Limited (l) PI Life Science Research Limited (m) PI Flowtech B.V. (n) PI Industries Management Consultancies LLC Dubai (o) PI Innoventures Limited (Formerly known as PILL Finance and Investments Limited) (p) PI Japan Co. Limited (q) PI Bioferma Private Limited (r) PI Fermachem Private Limited ;Controlled trust - PII ESOP Trust; Joint Venture - PI Kumiai Private Limited ; Associate - Solinnos Agro Sciences Private Limited. 4. The figures for the March quarter are the balancing figures between audited figures in respect of full financial year and the published unaudited year to date figures up to the third quarter of respective financial year. 5. The Company raised Rs 20,000 Mn during the quarter ended September 30, 2020 through Qualified Institutional Placement (QIP) of equity shares. Out of the funds received of Rs 19,750 Mn (net of expense of Rs 250 Mn), the Company invested Rs 18,419 Mn in its subsidiaries and Rs 1,331 Mn towards capital expenditure, thereby the entire QIP funds have been utilized during the year. 6. a) In April 2023, PI Health Sciences Limited (PIHS), a wholly owned subsidiary of the Company acquired 100% equity of Solis Pharmachem Private Limited and Therachem Research Medilab (India) Private Limited and specific assets of Therachem Research Medilab LLC, USA. The purchase consideration for the above included contingent consideration to be paid over a period of 6 years subject to achievement of specified business performance and to support for business development activities. Considering the performance of the acquired business since the acquisition, and the successful establishment of an experienced in-house global business development team, no longer requiring external business development support, the Company has renegotiated a mutually beneficial one-time settlement payment with erstwhile owners. This settlement has resulted in a write-back of the contingent consideration of Rs 1,260 million, which has been presented under Exceptional Item during the quarter ended December 31, 2025. b) Pursuant to the notification issued by the Ministry of Labour and Employment, multiple existing labour legislations have been consolidated into a unified framework comprising four Labour Codes, collectively referred to as the New Labour Codes which became effective from November 21, 2025. The Group has reassessed its employee benefit obligations in accordance with the revised definition of Wages. Considering that this impact is driven by a regulatory change and is non-recurring in nature, accordingly, an incremental liability of Rs 209 Mn has been recognised as an Exceptional Item during the quarter ended December 31, 2025 and Rs 20 Mn during the quarter ended March 31, 2026. The Ministry is in the process of notifying related rules to the New Labour Codes and impact of those will be evaluated and accounted for in the period in which they are notified. 7. Segment information as per Ind AS 108 Operating Segments is as per Annexure I. 8. The Board of Directors at their meeting held on May 19, 2026 have recommended final dividend of Rs 10 per equity share, subject to the approval of the shareholders in the ensuring Annual General Meeting. With this, total dividend for the year (including interim dividend of Rs 5 per equity share paid during the year) is Rs 15 per share. |
|---|
| Particulars | 3 months/ 6 month ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |||||
|---|---|---|---|---|---|---|---|
| Date of start of reporting period | 01-01-2026 | 01-04-2025 | |||||
| Date of end of reporting period | 31-03-2026 | 31-03-2026 | |||||
| Whether results are audited or unaudited | Audited | Audited | |||||
| Nature of report standalone or consolidated | Consolidated | Consolidated | |||||
| 1 | Segment Revenue (Income) | ||||||
| (net sale/income from each segment should be disclosed) | |||||||
| 1 | Agro Chemicals | 1,46,120.00 | 6,41,680.00 | ||||
| 2 | Pharma | 10,480.00 | 30,050.00 | ||||
| 3 | Inter segment adjustment | 0.00 | 0.00 | ||||
| Total Segment Revenue | 1,56,600.00 | 6,71,730.00 | |||||
| Less: Inter segment revenue | 80.00 | 360.00 | |||||
| Revenue from operations | 1,56,520.00 | 6,71,370.00 | |||||
| 2 | Segment Result | ||||||
| Profit (+) / Loss (-) before tax and interest from each segment | |||||||
| 1 | Agro Chemicals | 33,250.00 | 1,79,750.00 | ||||
| 2 | Pharma | (4,860.00) | (27,440.00) | ||||
| 3 | Inter segment adjustment | 1,860.00 | 6,990.00 | ||||
| Total Profit before tax | 30,250.00 | 1,59,300.00 | |||||
| i. Finance cost | |||||||
| ii. Other Unallocable Expenditure net off Unallocable income | 200.00 | (10,310.00) | |||||
| Profit before tax | 30,050.00 | 1,69,610.00 | |||||
| 3 | (Segment Asset - Segment Liabilities) | ||||||
| Segment Asset | |||||||
| 1 | Agro Chemicals | 11,97,360.00 | 11,97,360.00 | ||||
| 2 | Pharma | 1,47,010.00 | 1,47,010.00 | ||||
| 3 | Inter segment adjustment | 0.00 | 0.00 | ||||
| Total Segment Asset | 13,44,370.00 | 13,44,370.00 | |||||
| Un-allocable Assets | 0.00 | 0.00 | |||||
| Net Segment Asset | 13,44,370.00 | 13,44,370.00 | |||||
| 4 | Segment Liabilities | ||||||
| Segment Liabilities | |||||||
| 1 | Agro Chemicals | 1,81,150.00 | 1,81,150.00 | ||||
| 2 | Pharma | 40,170.00 | 40,170.00 | ||||
| 3 | Inter segment adjustment | 0.00 | 0.00 | ||||
| Total Segment Liabilities | 2,21,320.00 | 2,21,320.00 | |||||
| Un-allocable Liabilities | 0.00 | 0.00 | |||||
| Net Segment Liabilities | 2,21,320.00 | 2,21,320.00 | |||||
| Disclosure of notes on segments | Textual Information(2) | ||||||
| Textual Information(2) | Notes : The business of the Group is divided into two segments as below: a) Agro chemicals: Agro chemicals includes Agchem exports (CSM), Domestic Agri Brands and Biologicals b) Pharma: Pharma comprises Contract Research & Development, Contract Development and Manufacturing of Active, key starting materials and intermediates used in pharmaceutical industry. |
|---|
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-01-2026 | 01-04-2025 |
| B | Date of end of reporting period | 31-03-2026 | 31-03-2026 |
| C | Whether results are audited or unaudited | Audited | Audited |
| D | Nature of report standalone or consolidated | Consolidated | Consolidated |
| Other comprehensive income [Abstract] | |||
| 1 | Amount of items that will not be reclassified to profit and loss | ||
| 1 | Remeasurements gain/(loss) on defined benefits plans | (200.00) | 670.00 |
| Total Amount of items that will not be reclassified to profit and loss | (200.00) | 670.00 | |
| 2 | Income tax relating to items that will not be reclassified to profit or loss | (70.00) | 220.00 |
| 3 | Amount of items that will be reclassified to profit and loss | ||
| 1 | Effective portion of gain/(loss) on cash flow hedges | (12,570.00) | (22,290.00) |
| 2 | Exchange difference on translation of foreign operations | 4,240.00 | 12,000.00 |
| Total Amount of items that will be reclassified to profit and loss | (8,330.00) | (10,290.00) | |
| 4 | Income tax relating to items that will be reclassified to profit or loss | (4,400.00) | (7,800.00) |
| 5 | Total Other comprehensive income | (4,060.00) | (2,040.00) |
| Particulars | Year ended (dd-mm-yyyy) | |||||
|---|---|---|---|---|---|---|
| A | Date of start of reporting period | 01-04-2025 | ||||
| B | Date of end of reporting period | 31-03-2026 | ||||
| C | Whether results are audited or unaudited | Audited | ||||
| D | Nature of report standalone or consolidated | Consolidated | ||||
| Statement of cash flows | ||||||
| Cash flows from used in operating activities | ||||||
| Profit before tax | 1,69,040.00 | |||||
| Adjustments for reconcile profit (loss) | ||||||
| Adjustments for finance costs | 1,640.00 | |||||
| Adjustments for decrease (increase) in inventories | (23,280.00) | |||||
| Adjustments for decrease (increase) in trade receivables, current | (51,320.00) | |||||
| Adjustments for decrease (increase) in trade receivables, non-current | 0.00 | |||||
| Adjustments for decrease (increase) in other current assets | (5,940.00) | |||||
| Adjustments for decrease (increase) in other non-current assets | (60.00) | |||||
| Adjustments for other financial assets, non-current | 280.00 | |||||
| Adjustments for other financial assets, current | (3,630.00) | |||||
| Adjustments for other bank balances | 0.00 | |||||
| Adjustments for increase (decrease) in trade payables, current | (24,090.00) | |||||
| Adjustments for increase (decrease) in trade payables, non-current | 0.00 | |||||
| Adjustments for increase (decrease) in other current liabilities | (360.00) | |||||
| Adjustments for increase (decrease) in other non-current liabilities | 0.00 | |||||
| Adjustments for depreciation and amortisation expense | 40,660.00 | |||||
| Adjustments for impairment loss reversal of impairment loss recognised in profit or loss | 0.00 | |||||
| Adjustments for provisions, current | 0.00 | |||||
| Adjustments for provisions, non-current | 1,330.00 | |||||
| Adjustments for other financial liabilities, current | 11,210.00 | |||||
| Adjustments for other financial liabilities, non-current | 1,380.00 | |||||
| Adjustments for unrealised foreign exchange losses gains | 1,680.00 | |||||
| Adjustments for dividend income | 0.00 | |||||
| Adjustments for interest income | 20,850.00 | |||||
| Adjustments for share-based payments | 70.00 | |||||
| Adjustments for fair value losses (gains) | (5,120.00) | |||||
| Adjustments for undistributed profits of associates | 0.00 | |||||
| Other adjustments for which cash effects are investing or financing cash flow | 600.00 | |||||
| Other adjustments to reconcile profit (loss) | 0.00 | |||||
| Other adjustments for non-cash items | (9,370.00) | |||||
| Share of profit and loss from partnership firm or association of persons or limited liability partnerships | 0.00 | |||||
| Total adjustments for reconcile profit (loss) | (85,170.00) | |||||
| Net cash flows from (used in) operations | 83,870.00 | |||||
| Dividends received | 0.00 | |||||
| Interest paid | 0.00 | |||||
| Interest received | 0.00 | |||||
| Income taxes paid (refund) | 36,470.00 | |||||
| Other inflows (outflows) of cash | 0.00 | |||||
| Net cash flows from (used in) operating activities | 47,400.00 | |||||
| Cash flows from used in investing activities | ||||||
| Cash flows from losing control of subsidiaries or other businesses | 0.00 | |||||
| Cash flows used in obtaining control of subsidiaries or other businesses | 0.00 | |||||
| Other cash receipts from sales of equity or debt instruments of other entities | 0.00 | |||||
| Other cash payments to acquire equity or debt instruments of other entities | 0.00 | |||||
| Other cash receipts from sales of interests in joint ventures | 0.00 | |||||
| Other cash payments to acquire interests in joint ventures | 0.00 | |||||
| Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships | 0.00 | |||||
| Cash payment for investment in partnership firm or association of persons or limited liability partnerships | 0.00 | |||||
| Proceeds from sales of property, plant and equipment | 1,140.00 | |||||
| Purchase of property, plant and equipment | 1,11,780.00 | |||||
| Proceeds from sales of investment property | 0.00 | |||||
| Purchase of investment property | 0.00 | |||||
| Proceeds from sales of intangible assets | 0.00 | |||||
| Purchase of intangible assets | 0.00 | |||||
| Proceeds from sales of intangible assets under development | 0.00 | |||||
| Purchase of intangible assets under development | 0.00 | |||||
| Proceeds from sales of goodwill | 0.00 | |||||
| Purchase of goodwill | 0.00 | |||||
| Proceeds from biological assets other than bearer plants | 0.00 | |||||
| Purchase of biological assets other than bearer plants | 0.00 | |||||
| Proceeds from government grants | 0.00 | |||||
| Proceeds from sales of other long-term assets | 0.00 | |||||
| Purchase of other long-term assets | 0.00 | |||||
| Cash advances and loans made to other parties | 0.00 | |||||
| Cash receipts from repayment of advances and loans made to other parties | 0.00 | |||||
| Cash payments for future contracts, forward contracts, option contracts and swap contracts | 0.00 | |||||
| Cash receipts from future contracts, forward contracts, option contracts and swap contracts | 0.00 | |||||
| Dividends received | 0.00 | |||||
| Interest received | 20,850.00 | |||||
| Income taxes paid (refund) | 0.00 | |||||
| Other inflows (outflows) of cash | 28,440.00 | |||||
| Net cash flows from (used in) investing activities | (61,350.00) | |||||
| Cash flows from used in financing activities | ||||||
| Proceeds from changes in ownership interests in subsidiaries | 0.00 | |||||
| Payments from changes in ownership interests in subsidiaries | 0.00 | |||||
| Proceeds from issuing shares | 0.00 | |||||
| Proceeds from issuing other equity instruments | 0.00 | |||||
| Payments to acquire or redeem entity's shares | 0.00 | |||||
| Payments of other equity instruments | 0.00 | |||||
| Proceeds from exercise of stock options | 0.00 | |||||
| Proceeds from issuing debentures notes bonds etc | 0.00 | |||||
| Proceeds from borrowings | 11,640.00 | |||||
| Repayments of borrowings | 1,320.00 | |||||
| Payments of lease liabilities | 3,000.00 | |||||
| Dividends paid | 22,780.00 | |||||
| Interest paid | 1,640.00 | |||||
| Income taxes paid (refund) | 0.00 | |||||
| Other inflows (outflows) of cash | 0.00 | |||||
| Net cash flows from (used in) financing activities | (17,100.00) | |||||
| Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes | (31,050.00) | |||||
| Effect of exchange rate changes on cash and cash equivalents | ||||||
| Effect of exchange rate changes on cash and cash equivalents | 150.00 | |||||
| Net increase (decrease) in cash and cash equivalents | (30,900.00) | |||||
| Cash and cash equivalents cash flow statement at beginning of period | 59,230.00 | |||||
| Cash and cash equivalents cash flow statement at end of period | 28,330.00 | |||||
| Whether results are audited or unaudited | Audited |
|---|---|
| Declaration of unmodified opinion or statement on impact of audit qualification | Declaration of unmodified opinion |
| Auditor's opinion | |
| Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results | Yes |
| Sr No. | Audit firm's name | Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI | Certificate valid upto | ||
| 1 | Price waterhouse chartered Accountants LLP | Yes | 30-11-2026 | ||
|---|---|---|---|---|---|